KRT81 and viral infectious disease: The current preclinical vaccine candidate based on the Newcastle disease virus virus-like particle (VLP) platform is designed to generate neutralizing antibodies against viral attachment and fusion proteins K8.1, gB, and gH/gL to prevent viral infection (42, 43).